Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/1/2025

Prescribing Adderall in Patients with Methamphetamine Addiction History

Risk Assessment and Alternative Approaches

  • A history of substance use disorder, particularly methamphetamine addiction, significantly increases the risk of medication misuse and diversion, development of harmful drug-related behaviors, and relapse to methamphetamine use 1
  • The American Academy of Pediatrics recommends considering non-stimulant ADHD medications, such as atomoxetine (Strattera), extended-release guanfacine (Intuniv), and extended-release clonidine (Kapvay), as first-line treatment for patients with both ADHD and methamphetamine use disorder 2
  • Comprehensive addiction treatment, including linkage to addiction treatment and recovery resources, mental health services, behavioral therapy, and psychosocial support, should be prioritized for patients with methamphetamine use disorder 1
  • Careful evaluation and risk stratification, close monitoring and reassessment, and signed release for information exchange between providers are required when considering controlled substances in patients with addiction history 1